Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2021 Results - Earnings Call Transcript
02:55pm, Thursday, 06'th May 2021
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2021 Results - Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
09:47am, Thursday, 06'th May 2021
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -4.55% and -23.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the
Domino's, Editas, Roblox, Teva, US Steel and More Tuesday Afternoon Analyst Calls
12:16pm, Tuesday, 04'th May 2021
With the trading day more than halfway over, the broad markets were getting crushed.
Intellia Expands Its In Vivo Advantage
06:25am, Sunday, 02'nd May 2021
Intellia has optimized its core LNP technology to work across multiple targets within the liver.
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates
07:30am, Thursday, 29'th Apr 2021
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technolog
Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting
04:35pm, Tuesday, 27'th Apr 2021
- Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD)
CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today
03:51pm, Friday, 16'th Apr 2021
A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.
NTLA Stock Price Increased 10.61%: Why It Happened
08:59pm, Tuesday, 30'th Mar 2021
The stock price of Intellia Therapeutics Inc (NASDAQ: NTLA) has increased by 10.61%. This is why it happened.
CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technolog
Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
07:30am, Thursday, 25'th Mar 2021
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on its novel cytosine deaminase base editor technology at the
What's Next For Intellia Therapeutics Stock After A 15% Rise In A Week?
09:00am, Thursday, 18'th Mar 2021
The stock price of Intellia Therapeutics, a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a solid 15% rise over the last five trading days, while it is up 6%
Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today
01:26pm, Wednesday, 10'th Mar 2021
Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and ED
Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium
07:30am, Wednesday, 10'th Mar 2021
- Demonstrates the promise of Intellia's proprietary non-viral delivery system for in vivo genome editing of tissues outside the liver, with applications to inherited blood disorders such as sickle ce
Editas, Intellia: After Big Sell Off, Is it Time To Buy Gene Editing Stocks?
09:30am, Monday, 08'th Mar 2021
Our indicative theme of Gene Editing stocks is down by about 24% year-to-date, compared to the S&P 500 which has remained almost flat over the same period. The recent sell-off comes on the back of ris
Intellia Therapeutics Is At A Pivotal Moment
09:00am, Sunday, 07'th Mar 2021
Intellia reached clinical trials in early November 2020. The company will release initial data from NTLA-2001 sometime in the next several months.
